Welcome to the Wyoming Chapter of the American College of Cardiology
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- ACC CardiaCast: Improving Early FH Detection and Management From the ExpertsIn this episode, Drs. Christie Ballantyne and Anne Goldberg discuss updates on familial hypercholesterolemia (FH) diagnosis and management.
- COBRRA: Bleeding Risk Lower With Apixaban Than Rivaroxaban in VTE at 3 MonthsThe risk of clinically relevant bleeding was significantly lower with apixaban compared with rivaroxaban among patients with acute venous thromboembolism (VTE) during a three-month treatment period, according to results of the COBRRA trial published March 11 in NEJM.
- Is Epicardial Adipose Tissue Volume an Indicator of CAD?A recent study published in JACC: Cardiovascular Imaging found that high epicardial adipose tissue volume (EATv) is independently associated with the presence and progression of coronary artery disease (CAD), highlighting its value as a potential risk stratification marker for major cardiovascular events (MACE) and a therapeutic target for earlier or more intensive intervention.
- DOBERMANN: Are Tocilizumab, Dobutamine Effective in Reducing CS Risk in Patients With AMI?Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower […]
- CVD-COVID-UK/COVID-IMPACT Consortium: HF Outcomes Differ By Race, EthnicityIn an ethnically diverse nationwide registry of patients with heart failure (HF) receiving care in a universal health system, non-White patients, compared with White patients, were more likely to receive HF specialist care, be discharged on guideline-directed medical therapy (GDMT) and have a better prognosis...